{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T13:12:32Z","timestamp":1773493952474,"version":"3.50.1"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T00:00:00Z","timestamp":1762214400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T00:00:00Z","timestamp":1762214400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AAPS J"],"DOI":"10.1208\/s12248-025-01162-2","type":"journal-article","created":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T23:04:07Z","timestamp":1762297447000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Investigating Sulfotransferase Mediated Drug Interactions of Ethinylestradiol using a Physiologically Based Pharmacokinetic Model"],"prefix":"10.1208","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-0860-2534","authenticated-orcid":false,"given":"Harry P.","family":"Moore","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5747-5363","authenticated-orcid":false,"given":"Kuan-Fu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1923-8153","authenticated-orcid":false,"given":"Aki T.","family":"Heikkinen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8809-1960","authenticated-orcid":false,"given":"Sibylle","family":"Neuhoff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3023-2916","authenticated-orcid":false,"given":"Udoamaka","family":"Ezuruike","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3255-8925","authenticated-orcid":false,"given":"Jean","family":"Dinh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6050-8795","authenticated-orcid":false,"given":"Iain","family":"Gardner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hannah M.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4223-6754","authenticated-orcid":false,"given":"Felix","family":"Stader","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,4]]},"reference":[{"issue":"10348","key":"1162_CR1","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/S0140-6736(22)00936-9","volume":"400","author":"A Haakenstad","year":"2022","unstructured":"Haakenstad A, Angelino O, Irvine CMS, Bhutta ZA, Bienhoff K, Bintz C, et al. Measuring contraceptive method mix, prevalence, and demand satisfied by age and marital status in 204 countries and territories, 1970\u20132019: a systematic analysis for the global burden of disease study 2019. Lancet. 2022;400(10348):295\u2013327. https:\/\/doi.org\/10.1016\/S0140-6736(22)00936-9.","journal-title":"Lancet"},{"issue":"1","key":"1162_CR2","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1093\/oxfordjournals.aje.a115799","volume":"133","author":"BB Gerstman","year":"1991","unstructured":"Gerstman BB, Piper JM, Tomita DK, Ferguson WJ, Stadel BV, Lundin FE. Oral contraceptive estrogen dose and the risk of deep venous thromboembolic disease. Am J Epidemiol. 1991;133(1):32\u20137. https:\/\/doi.org\/10.1093\/oxfordjournals.aje.a115799.","journal-title":"Am J Epidemiol"},{"issue":"6","key":"1162_CR3","doi-asserted-by":"publisher","first-page":"467","DOI":"10.7326\/0003-4819-128-6-199803150-00008","volume":"128","author":"L Chasan-Taber","year":"1998","unstructured":"Chasan-Taber L, Stampfer MJ. Epidemiology of oral contraceptives and cardiovascular disease. Ann Intern Med. 1998;128(6):467\u201377. https:\/\/doi.org\/10.7326\/0003-4819-128-6-199803150-00008.","journal-title":"Ann Intern Med"},{"key":"1162_CR4","unstructured":"U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research. Clinical Drug Interaction Studies With Combined Oral Contraceptives Guidance for Industry: Guidance for Industry. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/clinical-drug-interaction-studies-combined-oral-contraceptives-guidance-industry. (2023). Accessed 25 June 2025"},{"issue":"3","key":"1162_CR5","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1111\/cts.12499","volume":"11","author":"N Zhang","year":"2018","unstructured":"Zhang N, Shon J, Kim MJ, Yu C, Zhang L, Huang SM, et al. Role of CYP3A in oral contraceptives clearance. Clin Transl Sci. 2018;11(3):251\u201360. https:\/\/doi.org\/10.1111\/cts.12499.","journal-title":"Clin Transl Sci"},{"issue":"1","key":"1162_CR6","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1002\/cpt.539","volume":"102","author":"E Luzon","year":"2017","unstructured":"Luzon E, Blake K, Cole S, Nordmark A, Versantvoort C, Berglund EG. Physiologically based pharmacokinetic modeling in regulatory decision-making at the European medicines agency. Clin Pharmacol Ther. 2017;102(1):98\u2013105. https:\/\/doi.org\/10.1002\/cpt.539.","journal-title":"Clin Pharmacol Ther"},{"key":"1162_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2024.106838","volume":"200","author":"Z Sun","year":"2024","unstructured":"Sun Z, Zhao N, Zhao X, Wang Z, Liu Z, Cui Y. Application of physiologically based pharmacokinetic modeling of novel drugs approved by the U.S. food and drug administration. Eur J Pharm Sci. 2024;200:106838. https:\/\/doi.org\/10.1016\/j.ejps.2024.106838.","journal-title":"Eur J Pharm Sci"},{"issue":"6","key":"1162_CR8","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1002\/cpt.1085","volume":"104","author":"U Ezuruike","year":"2018","unstructured":"Ezuruike U, Humphries H, Dickins M, Neuhoff S, Gardner I, Rowland Yeo K. Risk-benefit assessment of ethinylestradiol using a physiologically based pharmacokinetic modeling approach. Clin Pharmacol Ther. 2018;104(6):1229\u201339. https:\/\/doi.org\/10.1002\/cpt.1085.","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"1162_CR9","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1002\/psp4.13101","volume":"13","author":"GJ Lewis","year":"2024","unstructured":"Lewis GJ, Ahire D, Taskar KS. Physiologically-based pharmacokinetic modeling of prominent oral contraceptive agents and applications in drug-drug interactions. CPT: Pharmacometrics & Systems Pharmacology. 2024;13(4):563\u201375. https:\/\/doi.org\/10.1002\/psp4.13101.","journal-title":"CPT: Pharmacometrics & Systems Pharmacology"},{"issue":"7","key":"1162_CR10","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1177\/0091270009337131","volume":"49","author":"J Schwartz","year":"2009","unstructured":"Schwartz J, Hunt T, Smith WB, Wong P, Larson P, Crumley T, et al. The effect of etoricoxib on the pharmacokinetics of oral contraceptives in healthy participants. J Clin Pharmacol. 2009;49(7):807\u201315. https:\/\/doi.org\/10.1177\/0091270009337131.","journal-title":"J Clin Pharmacol"},{"issue":"4","key":"1162_CR11","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1002\/cpt.2689","volume":"112","author":"E Helmer","year":"2022","unstructured":"Helmer E, Karimian N, Van Assche K, Seghers I, Le Tallec S, Cherala G, et al. Ziritaxestat drug-drug interaction with oral contraceptives: role of SULT1E1 inhibition. Clin Pharmacol Ther. 2022;112(4):901\u20138. https:\/\/doi.org\/10.1002\/cpt.2689.","journal-title":"Clin Pharmacol Ther"},{"issue":"8","key":"1162_CR12","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1002\/jcph.2235","volume":"63","author":"D Rodrigues","year":"2023","unstructured":"Rodrigues D, Niosi M, Eng H, Healy C, Lazzaro S, Yang Q, et al. Attempting to Unmask the Inhibition of Sulfotransferase 1E1 in 17alpha-Ethinyl Estradiol Drug Interactions. J Clin Pharmacol. 2023;63(8):875\u20139. https:\/\/doi.org\/10.1002\/jcph.2235.","journal-title":"J Clin Pharmacol"},{"issue":"7","key":"1162_CR13","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1002\/psp4.12791","volume":"11","author":"U Ezuruike","year":"2022","unstructured":"Ezuruike U, Zhang M, Pansari A, De Sousa Mendes M, Pan X, Neuhoff S, et al. Guide to development of compound files for PBPK modeling in the Simcyp population-based simulator. CPT: Pharmacometrics & Systems Pharmacology. 2022;11(7):805\u201321. https:\/\/doi.org\/10.1002\/psp4.12791.","journal-title":"CPT: Pharmacometrics & Systems Pharmacology"},{"key":"1162_CR14","unstructured":"Bioinformatics\/Systems Biology group. PaxDb: Protein Abundance Database. https:\/\/pax-db.org\/. (2023). Accessed 1 September 2025"},{"issue":"1","key":"1162_CR15","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2024.2324485","volume":"16","author":"A Sepp","year":"2024","unstructured":"Sepp A, Muliaditan M. Application of quantitative protein mass spectrometric data in the early predictive analysis of membrane-bound target engagement by monoclonal antibodies. MAbs. 2024;16(1):2324485. https:\/\/doi.org\/10.1080\/19420862.2024.2324485.","journal-title":"MAbs"},{"issue":"11","key":"1162_CR16","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1124\/dmd.32.11","volume":"32","author":"ML Schrag","year":"2004","unstructured":"Schrag ML, Cui D, Rushmore TH, Shou M, Ma B, Rodrigues AD. Sulfotransferase 1E1 is a low km isoform mediating the 3-O-sulfation of ethinyl estradiol. Drug Metab Dispos. 2004;32(11):1299\u2013303. https:\/\/doi.org\/10.1124\/dmd.32.11.","journal-title":"Drug Metab Dispos"},{"issue":"4","key":"1162_CR17","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/s1093-3263(02)00163-8","volume":"21","author":"S Winiwarter","year":"2003","unstructured":"Winiwarter S, Ax F, Lennernas H, Hallberg A, Pettersson C, Karlen A. Hydrogen bonding descriptors in the prediction of human in vivo intestinal permeability. J Mol Graph Model. 2003;21(4):273\u201387. https:\/\/doi.org\/10.1016\/s1093-3263(02)00163-8.","journal-title":"J Mol Graph Model"},{"issue":"1","key":"1162_CR18","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1002\/jps.10005","volume":"91","author":"P Poulin","year":"2002","unstructured":"Poulin P, Theil FP. Prediction of pharmacokinetics prior to in vivo studies. 1. Mechanism-based prediction of volume of distribution. J Pharm Sci. 2002;91(1):129\u201356. https:\/\/doi.org\/10.1002\/jps.10005.","journal-title":"J Pharm Sci"},{"issue":"6","key":"1162_CR19","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1002\/jps.20073","volume":"93","author":"LM Berezhkovskiy","year":"2004","unstructured":"Berezhkovskiy LM. Volume of distribution at steady state for a linear pharmacokinetic system with peripheral elimination. J Pharm Sci. 2004;93(6):1628\u201340. https:\/\/doi.org\/10.1002\/jps.20073.","journal-title":"J Pharm Sci"},{"issue":"2","key":"1162_CR20","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1124\/dmd.31.2.224","volume":"31","author":"AD Rodrigues","year":"2003","unstructured":"Rodrigues AD, Halpin RA, Geer LA, Cui D, Woolf EJ, Matthews CZ, et al. Absorption, metabolism, and excretion of etoricoxib, a potent and selective cyclooxygenase-2 inhibitor, in healthy male volunteers. Drug Metab Dispos. 2003;31(2):224\u201332. https:\/\/doi.org\/10.1124\/dmd.31.2.224.","journal-title":"Drug Metab Dispos"},{"issue":"10","key":"1162_CR21","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1177\/0091270003257219","volume":"43","author":"NG Agrawal","year":"2003","unstructured":"Agrawal NG, Rose MJ, Matthews CZ, Woolf EJ, Porras AG, Geer LA, et al. Pharmacokinetics of etoricoxib in patients with hepatic impairment. J Clin Pharmacol. 2003;43(10):1136\u201348. https:\/\/doi.org\/10.1177\/0091270003257219.","journal-title":"J Clin Pharmacol"},{"issue":"6","key":"1162_CR22","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1124\/dmd.29.6.813","volume":"29","author":"K Kassahun","year":"2001","unstructured":"Kassahun K, McIntosh IS, Shou M, Walsh DJ, Rodeheffer C, Slaughter DE, et al. Role of human liver cytochrome P4503A in the metabolism of etoricoxib, a novel cyclooxygenase-2 selective inhibitor. Drug Metab Dispos. 2001;29(6):813\u201320. https:\/\/doi.org\/10.1124\/dmd.29.6.813.","journal-title":"Drug Metab Dispos"},{"issue":"1","key":"1162_CR23","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s00228-008-0556-9","volume":"65","author":"VV Hynninen","year":"2009","unstructured":"Hynninen VV, Olkkola KT, Neuvonen PJ, Laine K. Oral voriconazole and miconazole oral gel produce comparable effects on the pharmacokinetics and pharmacodynamics of etoricoxib. Eur J Clin Pharmacol. 2009;65(1):89\u201395. https:\/\/doi.org\/10.1007\/s00228-008-0556-9.","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"1162_CR24","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1177\/0091270003260338","volume":"44","author":"NG Agrawal","year":"2004","unstructured":"Agrawal NG, Matthews CZ, Mazenko RS, Kline WF, Woolf EJ, Porras AG, et al. Pharmacokinetics of etoricoxib in patients with renal impairment. J Clin Pharmacol. 2004;44(1):48\u201358. https:\/\/doi.org\/10.1177\/0091270003260338.","journal-title":"J Clin Pharmacol"},{"issue":"2","key":"1162_CR25","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1002\/cpdd.1021","volume":"11","author":"E Helmer","year":"2022","unstructured":"Helmer E, Willson A, Brearley C, Westerhof M, Delage S, Shaw I, et al. Pharmacokinetics and metabolism of Ziritaxestat (GLPG1690) in healthy male volunteers following intravenous and oral administration. Clin Pharmacol Drug Dev. 2022;11(2):246\u201356. https:\/\/doi.org\/10.1002\/cpdd.1021.","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"10","key":"1162_CR26","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1002\/jcph.1424","volume":"59","author":"E van der Aar","year":"2019","unstructured":"van der Aar E, Desrivot J, Dupont S, Heckmann B, Fieuw A, Stutvoet S, et al. Safety, pharmacokinetics, and pharmacodynamics of the autotaxin inhibitor GLPG1690 in healthy subjects: phase 1 randomized trials. J Clin Pharmacol. 2019;59(10):1366\u201378. https:\/\/doi.org\/10.1002\/jcph.1424.","journal-title":"J Clin Pharmacol"},{"issue":"5","key":"1162_CR27","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1007\/s11095-006-9210-3","volume":"24","author":"T Rodgers","year":"2007","unstructured":"Rodgers T, Rowland M. Mechanistic approaches to volume of distribution predictions: understanding the processes. Pharm Res. 2007;24(5):918\u201333. https:\/\/doi.org\/10.1007\/s11095-006-9210-3.","journal-title":"Pharm Res"},{"issue":"11","key":"1162_CR28","doi-asserted-by":"publisher","first-page":"2222","DOI":"10.1111\/cts.13622","volume":"16","author":"J Perrier","year":"2023","unstructured":"Perrier J, Gualano V, Helmer E, Namour F, Lukacova V, Taneja A. Drug-drug interaction prediction of ziritaxestat using a physiologically based enzyme and transporter pharmacokinetic network interaction model. Clin Transl Sci. 2023;16(11):2222\u201335. https:\/\/doi.org\/10.1111\/cts.13622.","journal-title":"Clin Transl Sci"},{"issue":"23","key":"1162_CR29","doi-asserted-by":"publisher","first-page":"3099","DOI":"10.1016\/0006-2952(73)90196-2","volume":"22","author":"Y Cheng","year":"1973","unstructured":"Cheng Y, Prusoff WH. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol. 1973;22(23):3099\u2013108. https:\/\/doi.org\/10.1016\/0006-2952(73)90196-2.","journal-title":"Biochem Pharmacol"},{"key":"1162_CR30","unstructured":"European Medicines Agency. Etoricoxib - Article 31 referral - Annex I, II, III. https:\/\/www.ema.europa.eu\/en\/documents\/referral\/etoricoxib-article-31-referral-annex-i-ii-iii_en.pdf. (2008). Accessed 25 June 2025"},{"issue":"1","key":"1162_CR31","doi-asserted-by":"publisher","DOI":"10.1136\/bmjresp-2019-000422","volume":"6","author":"TM Maher","year":"2019","unstructured":"Maher TM, Kreuter M, Lederer DJ, Brown KK, Wuyts W, Verbruggen N, et al. Rationale, design and objectives of two phase III, randomised, placebo-controlled studies of GLPG1690, a novel autotaxin inhibitor, in idiopathic pulmonary fibrosis (ISABELA 1 and 2). BMJ Open Respir Res. 2019;6(1):e000422. https:\/\/doi.org\/10.1136\/bmjresp-2019-000422.","journal-title":"BMJ Open Respir Res"},{"issue":"2","key":"1162_CR32","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1124\/dmd.110.036103","volume":"39","author":"EJ Guest","year":"2011","unstructured":"Guest EJ, Aarons L, Houston JB, Rostami-Hodjegan A, Galetin A. Critique of the two-fold measure of prediction success for ratios: application for the assessment of drug-drug interactions. Drug Metab Dispos. 2011;39(2):170\u20133. https:\/\/doi.org\/10.1124\/dmd.110.036103.","journal-title":"Drug Metab Dispos"},{"issue":"7","key":"1162_CR33","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1124\/dmd.120.090738","volume":"48","author":"H Zhang","year":"2020","unstructured":"Zhang H, Wolford C, Basit A, Li AP, Fan PW, Murray BP, et al. Regional proteomic quantification of clinically relevant non-cytochrome P450 enzymes along the human small intestine. Drug Metab Dispos. 2020;48(7):528\u201336. https:\/\/doi.org\/10.1124\/dmd.120.090738.","journal-title":"Drug Metab Dispos"},{"issue":"3","key":"1162_CR34","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/s0041-008x(02)00073-x","volume":"187","author":"G Chen","year":"2003","unstructured":"Chen G, Zhang D, Jing N, Yin S, Falany CN, Radominska-Pandya A. Human gastrointestinal sulfotransferases: identification and distribution. Toxicol Appl Pharmacol. 2003;187(3):186\u201397. https:\/\/doi.org\/10.1016\/s0041-008x(02)00073-x.","journal-title":"Toxicol Appl Pharmacol"},{"issue":"6","key":"1162_CR35","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1111\/bcp.12745","volume":"80","author":"H Wiesinger","year":"2015","unstructured":"Wiesinger H, Berse M, Klein S, Gschwend S, H\u00f6chel J, Zollmann FS, et al. Pharmacokinetic interaction between the CYP3A4 inhibitor ketoconazole and the hormone drospirenone in combination with ethinylestradiol or estradiol. Br J Clin Pharmacol. 2015;80(6):1399\u2013410. https:\/\/doi.org\/10.1111\/bcp.12745.","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"1162_CR36","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/0010-7824(79)90098-2","volume":"20","author":"D Back","year":"1979","unstructured":"Back D, Breckenridge A, Crawford FE, MacIver M, Rowe P, Watts MJ. An investigation of the pharmacokinetics of ethynylestsadiol in women using badioimmunoassay. Contraception. 1979;20(3):263\u201373. https:\/\/doi.org\/10.1016\/0010-7824(79)90098-2.","journal-title":"Contraception"},{"issue":"1","key":"1162_CR37","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/0010-7824(95)00252-9","volume":"53","author":"A Weber","year":"1996","unstructured":"Weber A, J\u00e4ger R, B\u00f6rner A, Klinger G, Vollanth R, Matthey K, et al. Can grapefruit juice influence ethinylestradiol bioavailability? Contraception. 1996;53(1):41\u20137. https:\/\/doi.org\/10.1016\/0010-7824(95)00252-9.","journal-title":"Contraception"},{"issue":"2","key":"1162_CR38","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1046\/j.1365-2125.1998.00749.x","volume":"46","author":"D Ouellet","year":"1998","unstructured":"Ouellet D, Hsu A, Qian J, Locke CS, Eason CJ, Cavanaugh JH, et al. Effect of ritonavir on the pharmacokinetics of ethinyl oestradiol in healthy female volunteers. Br J Clin Pharmacol. 1998;46(2):111\u20136. https:\/\/doi.org\/10.1046\/j.1365-2125.1998.00749.x.","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"1162_CR39","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/s0002-9378(98)80016-1","volume":"178","author":"FE Sinofsky","year":"1998","unstructured":"Sinofsky FE, Pasquale SA. The effect of fluconazole on circulating ethinyl estradiol levels in women taking oral contraceptives. Am J Obstet Gynecol. 1998;178(2):300\u20134. https:\/\/doi.org\/10.1016\/s0002-9378(98)80016-1.","journal-title":"Am J Obstet Gynecol"},{"issue":"4","key":"1162_CR40","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/s0009-9236(99)70138-4","volume":"65","author":"P Barditch-Crovo","year":"1999","unstructured":"Barditch-Crovo P, Trapnell CB, Ette E, Zacur HA, Coresh J, Rocco LE, et al. The effects of rifampin and rifabutin on the pharmacokinetics and pharmacodynamics of a combination oral contraceptive. Clin Pharmacol Ther. 1999;65(4):428\u201338. https:\/\/doi.org\/10.1016\/s0009-9236(99)70138-4.","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"1162_CR41","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/s0029-7844(01)01443-0","volume":"98","author":"J Hilbert","year":"2001","unstructured":"Hilbert J, Messig M, Kuye O, Friedman H. Evaluation of interaction between fluconazole and an oral contraceptive in healthy women. Obstet Gynecol. 2001;98(2):218\u201323. https:\/\/doi.org\/10.1016\/s0029-7844(01)01443-0.","journal-title":"Obstet Gynecol"},{"issue":"6","key":"1162_CR42","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1177\/00912700122010456","volume":"41","author":"AML Inglis","year":"2001","unstructured":"Inglis AML, Miller AK, Culkin KT, Finnerty D, Patterson SD, Jorkasky DK, et al. Lack of effect of rosiglitazone on the pharmacokinetics of oral contraceptives in healthy female volunteers. J Clin Pharmacol. 2001;41(6):683\u201390. https:\/\/doi.org\/10.1177\/00912700122010456.","journal-title":"J Clin Pharmacol"},{"issue":"4","key":"1162_CR43","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1177\/135965350801300415","volume":"13","author":"VJ Sekar","year":"2008","unstructured":"Sekar VJ, Lefebvre E, Guzman SS, Felicione E, De Pauw M, Vangeneugden T, et al. Pharmacokinetic interaction between ethinyl estradiol, norethindrone and darunavir with low-dose ritonavir in healthy women. Antivir Ther. 2008;13(4):563\u20139. https:\/\/doi.org\/10.1177\/135965350801300415.","journal-title":"Antivir Ther"},{"issue":"4","key":"1162_CR44","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1046\/j.1528-1157.2003.55602.x","volume":"44","author":"DR Doose","year":"2003","unstructured":"Doose DR, Wang SS, Padmanabhan M, Schwabe S, Jacobs D, Bialer M. Effect of topiramate or carbamazepine on the pharmacokinetics of an oral contraceptive containing norethindrone and ethinyl estradiol in healthy obese and nonobese female subjects. Epilepsia. 2003;44(4):540\u20139. https:\/\/doi.org\/10.1046\/j.1528-1157.2003.55602.x.","journal-title":"Epilepsia"},{"key":"1162_CR45","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1007\/s00228-014-1711-0","volume":"70","author":"WH Lin","year":"2014","unstructured":"Lin WH, Feng H-P, Shadle CR, O\u2019Reilly T, Wagner JA, Butterton JR. Pharmacokinetic and pharmacodynamic interactions between the hepatitis C virus protease inhibitor, boceprevir, and the oral contraceptive ethinyl estradiol\/norethindrone. Eur J Clin Pharmacol. 2014;70:1107\u201313. https:\/\/doi.org\/10.1007\/s00228-014-1711-0.","journal-title":"Eur J Clin Pharmacol"},{"issue":"10","key":"1162_CR46","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1016\/j.clinthera.2011.08.012","volume":"33","author":"C Kasserra","year":"2011","unstructured":"Kasserra C, Li J, March B, O\u2019Mara E. Effect of vicriviroc with or without ritonavir on oral contraceptive pharmacokinetics: a randomized, open-label, parallel-group, fixed-sequence crossover trial in healthy women. Clin Ther. 2011;33(10):1503\u201314. https:\/\/doi.org\/10.1016\/j.clinthera.2011.08.012.","journal-title":"Clin Ther"},{"issue":"10","key":"1162_CR47","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1177\/0091270011419855","volume":"52","author":"V Garg","year":"2012","unstructured":"Garg V, van Heeswijk R, Yang Y, Kauffman R, Smith F, Adda N. The pharmacokinetic interaction between an oral contraceptive containing ethinyl estradiol and norethindrone and the HCV protease inhibitor telaprevir. J Clin Pharmacol. 2012;52(10):1574\u201383. https:\/\/doi.org\/10.1177\/0091270011419855.","journal-title":"J Clin Pharmacol"},{"issue":"4","key":"1162_CR48","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1177\/00912709922007985","volume":"39","author":"CM Loi","year":"1999","unstructured":"Loi CM, Stern R, Koup JR, Vassos AB, Knowlton P, Sedman AJ. Effect of troglitazone on the pharmacokinetics of an oral contraceptive agent. J Clin Pharmacol. 1999;39(4):410\u20137. https:\/\/doi.org\/10.1177\/00912709922007985.","journal-title":"J Clin Pharmacol"},{"issue":"2","key":"1162_CR49","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1124\/jpet.117.247296","volume":"365","author":"JE Moscovitz","year":"2018","unstructured":"Moscovitz JE, Kalgutkar AS, Nulick K, Johnson N, Lin Z, Goosen TC, et al. Establishing transcriptional signatures to differentiate PXR-, CAR-, and AhR-mediated regulation of drug metabolism and transport genes in cryopreserved human hepatocytes. J Pharmacol Exp Ther. 2018;365(2):262\u201371. https:\/\/doi.org\/10.1124\/jpet.117.247296.","journal-title":"J Pharmacol Exp Ther"},{"issue":"19","key":"1162_CR50","doi-asserted-by":"publisher","first-page":"8392","DOI":"10.1093\/nar\/gkr458","volume":"39","author":"S Kodama","year":"2011","unstructured":"Kodama S, Hosseinpour F, Goldstein JA, Negishi M. Liganded pregnane X receptor represses the human sulfotransferase SULT1E1 promoter through disrupting its chromatin structure. Nucleic Acids Res. 2011;39(19):8392\u2013403. https:\/\/doi.org\/10.1093\/nar\/gkr458.","journal-title":"Nucleic Acids Res"}],"container-title":["The AAPS Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12248-025-01162-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1208\/s12248-025-01162-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12248-025-01162-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T16:21:00Z","timestamp":1770826860000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1208\/s12248-025-01162-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,4]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1]]}},"alternative-id":["1162"],"URL":"https:\/\/doi.org\/10.1208\/s12248-025-01162-2","relation":{},"ISSN":["1550-7416"],"issn-type":[{"value":"1550-7416","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,4]]},"assertion":[{"value":"27 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors are employees of Certara and may hold shares in the company.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"13"}}